Combined treatment strategy targeting glioblastoma cancer stem cells by modulating mTOR, MGMT, VEGF, AKT, STAT3, Wnt and P53.

Researcher: Dr. Marcos Escosa Bagé.

Start: January / 2020.

Status:  Active. No Recruiting

Duration:  Variable (1-3 years).

Type of study:  Prospective without control cases.

General description of the study: Based on the results of other treatment protocols such as CUSP9, the effect of renin angiotensin system inhibitors, Wnt inhibitors or the recent results of the antiapoptotic effect obtained with serotonin reuptake inhibitors and natural antioxidants, that have been shown to improve the efficacy of classic treatment with temozolamide (Stupp protocol), we have selected the medications with the most antitumor potential demonstrated in different studies or clinical trials, hoping to obtain better results.

In this investigation  we applied a treatment based on a novel combination of drugs that attack glioblastoma stem cells by inhibiting different signaling pathways synergistically.

This combination is carried out in a strategic way, depending on when the patient is in the standard treatment with chemotherapy and/or radiotherapy, since it acts by potentiating it and reducing at the same time the resistance to it mediated by the stem cells.

All medications used in this protocol act against glioblastoma stem cells. Each medication acts through different mechanisms, so that the therapeutic effect is given by multiple routes of action that weaken tumor proliferation and facilitate the action of classical chemotherapy.

This treatment is based on the combination of different drugs, approved by the FDA (Food and Drug Administration) for cancer, combined with potent antioxidants that have been shown to improve resistance to temozolomide and radiotherapy. 

Medication dosage:  Progressive, individualized and adapted.

Evolution control:  By weekly Karnofsky scale and brain MRI with contrast in the same periods as the Stupp protocol. Blood test: basic, renal and hepatic profile weekly until treatment stabilizes. Daily control of blood pressure.

Medication administration:  All medications are taken orally.

Medication dosage:  Progressive, individualized and adapted.

Patient information:  Yes.

Informed consent:  Yes.

Revised scientific evidence:  Yes

Tracking: Yes

Review: Yes

Bibliography:

Strepkos D, Markouli M, Klonou A, Piper C, Papavassiliou AG. Insights in the

immunobiology of glioblastoma. J Mol Med (Berl). 2020 Jan;98(1):1-10.

 

Neamati F, Asemi Z. The effects of melatonin on signaling pathways and

molecules involved in glioma. Fundam Clin Pharmacol. 2019 Dec 6.

 

Piper C, Papavassiliou KA, Papavassiliou AG. Pivotal Role of STAT3 in Shaping

Glioblastoma Immune Microenvironment. Cells. 2019 Nov 6;8(11).

 

Yang K, Niu L, Bai Y, Le W. Glioblastoma: Targeting the autophagy in

tumorigenesis. Brain Res Bull. 2019 Nov;153:334-340.

 

Le Rhun E, Preusser M, Roth P, Reardon DA, van den Bent M, Wen P, Reifenberger

G, Weller M. Molecular targeted therapy of glioblastoma. Cancer Treat Rev. 2019

Nov;80:101896.

 

Skaga E, Skaga IØ, Grieg Z, Sandberg CJ, Langmoen IA, Vik-Mo EO. The efficacy

of a coordinated pharmacological blockade in glioblastoma stem cells with nine

repurposed drugs using the CUSP9 strategy. J Cancer Res Clin Oncol. 2019

Jun;145(6):1495-1507.

 

Tan DC, Roth IM, Wickremesekera AC, Davis PF, Kaye AH, Mantamadiotis T, Stylli

SS, Tan ST. Therapeutic Targeting of Cancer Stem Cells in Human Glioblastoma by

Manipulating the Renin-Angiotensin System. Cells. 2019 Oct 31;8(11).

 

Kwon S, Yoo KH, Sym SJ, Khang D. Mesenchymal stem cell therapy assisted by

nanotechnology: a possible combinational treatment for brain tumor and central

nerve regeneration. Int J Nanomedicine. 2019 Jul 29;14:5925-5942.

 

Ngadiono E, Hardiany NS. Advancing towards Effective Glioma Therapy: MicroRNA

Derived from Umbilical Cord Mesenchymal Stem Cells' Extracellular Vesicles.

Malays J Med Sci. 2019 Jul; 26 (4): 5-16.

 

Matarredona ER, Pastor AM. Neural Stem Cells of the Subventricular Zone as the

Origin of Human Glioblastoma Stem Cells. Therapeutic Implications. Front Oncol.

2019 Aug 20;9:779.

 

Ryskalin L, Gaglione A, Limanaqi F, Biagioni F, Family P, Friars A, Esposito

V, Fornai F. The Autophagy Status of Cancer Stem Cells in Gliobastoma Multiforme:

From Cancer Promotion to Therapeutic Strategies. Int J Mol Sci. 2019 Aug

5;20(15).

 

Jackson CM, Choi J, Lim M. Mechanisms of immunotherapy resistance: lessons

from glioblastoma. Nat Immunol. 2019 Sep;20(9):1100-1109.

 

Fan X, Xiong Y, Wang Y. A reignited debate over the cell(s) of origin for

glioblastoma and its clinical implications. Front Med. 2019 Oct;13(5):531-539.

 

Gimple RC, Bhargava S, Dixit D, Rich JN. Glioblastoma stem cells: lessons

from the tumor hierarchy in a lethal cancer. Genes Dev. 2019 Jun

1;33(11-12):591-609.

 

Brown DV, Stylli SS, Kaye AH, Mantamadiotis T. Multilayered Heterogeneity of

Glioblastoma Stem Cells: Biological and Clinical Significance. Adv Exp Med Biol.

2019;1139:1-21.

 

Sharifzad F, Ghavami S, Verdi J, Mardpour S, Mollapour Sisakht M, Azizi Z,

Taghikhani A, MJos MJ, Fakharian E, Ebrahimi M, Hamidieh AA. Glioblastoma cancer

stem cell biology: Potential theranostic targets. Drug Resist Updat. 2019

Jan;42:35-45.

 

van Schaijik B, Wickremesekera AC, Mantamadiotis T, Kaye AH, Tan ST, Stylli

SS, Itinteang T. Circulating tumor stem cells and glioblastoma: A review. J Clin

Neurosci. 2019 Mar;61:5-9.

Seyithanoğlu MH, Abdallah A, Kitiş S, Güler EM, Koçyiğit A, Dündar TT,

Gündağ Papaker M. Investigation of cytotoxic, genotoxic, and apoptotic effects of

curcumin on glioma cells. Cell Mol Biol (Noisy-le-grand). 2019 Mar 31;65(3):101-108.

 

Vengoji R, Ponnusamy MP, Rachagani S, Mahapatra S, Batra SK, Shonka N, Macha

MA. Novel therapies hijack the blood-brain barrier to eradicate glioblastoma

cancer stem cells. Carcinogenesis. 2019 Mar 12;40(1):2-14.

 

Skoda J, Borankova K, Jansson PJ, Huang ML, Veselska R, Richardson DR.

Pharmacological targeting of mitochondria in cancer stem cells: An ancient

organelle at the crossroad of novel anti-cancer therapies. Pharmacol Res. 2019

Jan;139:298-313.

 

Ghosh D, Nandi S, Bhattacharjee S. Combination therapy to checkmate

Glioblastoma: clinical challenges and advances. Clin Transl Med. 2018 Oct

16;7(1):33.

 

Balça-Silva J, Matias D, Carmo AD, Sarmento-Ribeiro AB, Lopes MC, Moura-Neto

V. Cellular and molecular mechanisms of glioblastoma malignancy: Implications in

resistance and therapeutic strategies. Semin Cancer Biol. 2019 Oct;58:130-141.

 

Tompa M, Kalovits F, Nagy A, Kalman B. Contribution of the Wnt Pathway to

Defining Biology of Glioblastoma. Neuromolecular Med. 2018 Dec;20(4):437-451.

 

Sotgia F, Ozsvari B, Fiorillo M, De Francesco EM, Bonuccelli G, Lisanti MP. A

mitochondrial based oncology platform for targeting cancer stem cells (CSCs):

MITO-ONC-RX. Cell Cycle. 2018;17(17):2091-2100.

 

Weyerhäuser P, Kantelhardt SR, Kim EL. Re-purposing Chloroquine for

Glioblastoma: Potential Merits and Confounding Variables. Front Oncol. 2018 Aug

27;8:335.

 

Song CG, Zhang YZ, Wu HN, Cao XL, Guo CJ, Li YQ, Zheng MH, Han H. Stem cells:

a promising candidate to treat neurological disorders. Neural Regen Res. 2018

Jul;13(7):1294-1304.

He L, Zhao C, Yan M, Zhang LY, Xia YZ. Inhibition of P-glycoprotein function

by procyanidine on blood-brain barrier. Phytother Res. 2009 Jul;23(7):933-7.

Ham SW, Kim JK, Jeon HY, Kim EJ, Jin X, Eun K, Park CG, Lee SY, Seo S, Kim JY, Choi SH,

Hong N, Lee YY, Kim H. Korean Red ginseng extract inhibits glioblastoma propagation

by blocking the Wnt signaling pathway. J Ethnopharmacol. 2019 May 23;236:393-400.

 

Elmaci I, Altinoz MA. Targeting the cellular schizophrenia. Likely employment

of the antipsychotic agent pimozide in treatment of refractory cancers and

glioblastoma. Crit Rev Oncol Hematol. 2018 Aug;128:96-109.

 

Vengoji R, Macha MA, Batra SK, Shonka NA. Natural products: a hope for

glioblastoma patients. Oncotarget. 2018 Apr 24;9(31):22194-22219.

 

Cai X, Sughrue ME. Glioblastoma: new therapeutic strategies to address

cellular and genomic complexity. Oncotarget. 2017 Dec 20;9(10):9540-9554.

 

Jo J, Wen PY. Antiangiogenic Therapy of High-Grade Gliomas. Prog Neurol Surg.

2018;31:180-199.

 

Stoyanov GS, Dzhenkov D, Ghenev P, Iliev B, Enchev Y, Tonchev AB. Cell

biology of glioblastoma multiforme: from basic science to diagnosis and

treatment. With Oncol. 2018 Jan 31; 35 (3): 27.

Roy NK, Parama D, Banik K, Bordoloi D, Devi AK, Thakur KK, Padmavathi G,

Shakibaei M, Fan L, Sethi G, Kunnumakkara AB. An Update on Pharmacological Potential

of Boswellic Acids against Chronic Diseases. Int J Mol Sci. 2019 Aug 22;20(17).

Bioethical principles: This study complies with the  International Code of Medical Ethics  and ethical principles for medical research in humans according to the Helsinki Declaration.

Financing:  Study not supported or financed by any laboratory or lucrative entity.

Página revisada el 19 de Mayo del 2020

Málaga, España (Spain)

  • Facebook
  • Instagram